Medifast (MED) Tops Q2 EPS by 133c, beats revenue, provides outlook

Medifast (NYSE: MED) reported Q2 EPS of $2.77, $1.33 better than the analyst estimate of $1.44. Revenue for the quarter came in at $296.19 million versus the consensus estimate of $270.2 million.

Third Quarter 2023 Outlook

The Company expects third quarter 2023 revenue to be in the range of $220 million to $240 million and third quarter 2023 diluted EPS to be in the range of $0.71 to $1.32 The third quarter 2023 earnings guidance assumes a 23.0% to 25.0% effective tax rate. The guidance includes the impact of investments being made for future growth initiatives, which are expected to continue throughout the year, impacting profitability.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c